The Amyloidosis Research Consortium is a nonprofit accelerating the development of and access to new and innovative treatments. We are driving the research that will have the greatest impact on length and quality of life for patients.
Latest news from ARC
Coronavirus: What Amyloidosis Patients Should Know
With the rise in cases of COVID-19, and the risks posed to some amyloidosis patients, ARC is monitoring recommendations and resources.
ARC Launches HTA Toolkit for Patient Advocates
ARC has published a Health Technology Assessment Toolkit to equip patients and patient groups within Europe, as well as globally, with the tools to advocate on behalf of themselves and other patients for access to new treatments.
ARC attends inaugural AfPA meeting
On February 8, 2020, ARC’s Manager of Healthcare and Education, Lori Bulpett, attended the inaugural Rare Disease Working Group Meeting, hosted by the Alliance for Patient Access (AfPA), in Washington, DC. The meeting's focus was on amyloidosis and the various issues that patients face in accessing treatment options.
My Amyloidosis Pathfinder
MAP is a free, easy-to-use tool that captures your treatment preferences, goals, and challenges so you can effectively communicate with your amyloidosis care teams. You can also find and compare specialty treatment centers and receive personalized matches to clinical trials.Get Started